Enliven Therapeutics (NASDAQ: ELVN)
$19.54
(-1.9%)
-$0.38
Price as of October 3, 2025, 3:58 p.m. ET
Enliven Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Enliven Therapeutics Company Info
Enliven Therapeutics, Inc. operates as a clinical stage precision oncology company. It is focused on the discovery and development of next-generation small molecule kinase inhibitors and advancing Enliven's pipeline of precision oncology product candidates. The company was founded in June 2019 and is headquartered in Boulder, CO.
News & Analysis
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.